Stereotactic body radiotherapy for centrally‑located lung tumors with 56 Gy in seven fractions: A retrospective study

Aoki,Shuri; Yamashita,Hideomi; Haga,Akihiro; Ota,Takeshi; Takahashi,Wataru; Ozaki,Sho; Nawa,Kanabu; Imae,Toshikazu; Abe,Osamu; Nakagawa,Keiichi

doi:10.3892/ol.2018.9188

Stereotactic body radiotherapy for centrally‑located lung tumors with 56 Gy in seven fractions: A retrospective study

Authors:
- Shuri Aoki
- Hideomi Yamashita
- Akihiro Haga
- Takeshi Ota
- Wataru Takahashi
- Sho Ozaki
- Kanabu Nawa
- Toshikazu Imae
- Osamu Abe
- Keiichi Nakagawa
View Affiliations

Affiliations: Department of Radiology, University of Tokyo Hospital, Tokyo 113‑8655, Japan, Medical and Dentistry Laboratory, University of Tokushima, Tokushima 770‑8501, Japan
Published online on: July 23, 2018 https://doi.org/10.3892/ol.2018.9188
Pages: 4498-4506
Copyright: © Aoki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stereotactic body radiotherapy (SBRT) for centrally‑located lung tumors remains a challenge because of the increased risk of treatment‑related adverse events (AEs), and uncertainty around prescribing the optimal dose. The present study reported the results of central tumor SBRT with 56 Gy in 7 fractions (fr) at the University of Tokyo Hospital. A total of 35 cases that underwent SBRT with or without volumetric‑modulated arc therapy consisting of 56 Gy/7 fr for central lung lesions between 2010 and 2016 at the University of Tokyo Hospital were reveiwed. A central lesion was defined as a tumor within 2 cm of the proximal bronchial tree (RTOG 0236 definition) or within 2 cm in all directions of any critical mediastinal structure. Local control (LC), overall survival (OS), and AEs were investigated. The Kaplan‑Meier method was used to estimate LC and OS. AEs were scored per the Common Terminology Criteria for Adverse Events Version 4.0. Thirty‑five patients with 36 central lung lesions were included. Fifteen lesions were primary non‑small cell lung cancer (NSCLC), 13 were recurrences of NSCLC, and 8 had oligo‑recurrences from other primaries. Median tumor diameter was 29 mm. Eighteen patients had had prior surgery. At a median follow‑up of 13.1 months for all patients and 18.3 months in surviving patients, 22 patients had died, ten due to primary disease (4 NSCLC), while three were treatment‑related. The 1‑ and 2‑year OS were 57.3 and 40.4%, respectively, and median OS was 15.7 months. Local recurrence occurred in only two lesions. 1‑ and 2‑year LC rates were both 96%. Nine patients experienced grade ≥3 toxicity, representing 26% of the cohort. Two of these were grade 5, one pneumonitis and one hemoptysis. Considering the background of the subject, tumor control of our central SBRT is promising, especially in primary NSCLC. However, the safety of SBRT to central lung cancer remains controversial.

View Figures

View References

1	de Perrot M, Licker M, Reymond MA, Robert J and Spiliopoulos A: Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J. 14:419–422. 1999. View Article : Google Scholar : PubMed/NCBI
2	Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol. 16:630–637. 2015. View Article : Google Scholar : PubMed/NCBI
3	Dahele M, Hatton M, Slotman B and Guckenberger M: Stereotactic body radiotherapy: A survey of contemporary practice in six selected European countries. Acta Oncol. 54:1237–1241. 2015. View Article : Google Scholar : PubMed/NCBI
4	Daly ME, Perks JR and Chen AM: Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol. 8:202–207. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chang JY, Bezjak A and Mornex F: IASLC Advanced radiation technology committee: Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: What we have learned. J Thorac Oncol. 10:577–585. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ and van As NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 14:e28–e37. 2013. View Article : Google Scholar : PubMed/NCBI
7	Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R and Weichselbaum R: The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 11:549–557. 2014. View Article : Google Scholar : PubMed/NCBI
8	Niibe Y and Hayakawa K: Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J Clin Oncol. 40:107–111. 2010. View Article : Google Scholar : PubMed/NCBI
9	Niibe Y and Chang JY: Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012:2610962012. View Article : Google Scholar : PubMed/NCBI
10	Roesch J, Panje C, Sterzing F, Mantel F, Nestle U, Andratschke N and Guckenberger M: SBRT for centrally localized NSCLC- What is too central? Radiat Oncol. 11:1572016. View Article : Google Scholar : PubMed/NCBI
11	Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Smythe WR and Putnam JB Jr: Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg. 71:1105–1112. 2001. View Article : Google Scholar : PubMed/NCBI
12	Saito M, Furukawa K, Miura T and Kato H: Evaluation of T factor, surgical method, and prognostic factors in central type lung cancer. Jpn J Thorac Cardiovasc Surg. 50:413–417. 2002. View Article : Google Scholar : PubMed/NCBI
13	Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M and Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 24:4833–4839. 2006. View Article : Google Scholar : PubMed/NCBI
14	Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, Hara WY, Trakul N, Loo BW Jr and Diehn M: Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer. 89:50–56. 2015. View Article : Google Scholar : PubMed/NCBI
15	Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, Videtic GM and Bradley J: No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: An analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 88:1092–1099. 2014. View Article : Google Scholar : PubMed/NCBI
16	Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
17	Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, et al: Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 90:1168–1176. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wheldon TE, Deehan C, Wheldon EG and Barrett A: The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol. 46:285–295. 1998. View Article : Google Scholar : PubMed/NCBI
19	Yamashita H, Takahashi W, Haga A, Kida S, Saotome N and Nakagawa K: Stereotactic body radiotherapy for small lung tumors in the university of Tokyo hospital. Biomed Res Int. 2014:1365132014. View Article : Google Scholar : PubMed/NCBI
20	Nakagawa K, Haga A, Sakumi A, Yamashita H, Igaki H, Shiraki T, Ohtomo K, Iwai Y and Yoda K: Impact of flattening-filter-free techniques on delivery time for lung stereotactic volumetric modulated arc therapy and image quality of concurrent kilovoltage cone-beam computed tomography: A preliminary phantom study. J Radiat Res. 55:200–202. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yamashita H, Takahashi W, Haga A and Nakagawa K: Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol. 6:708–715. 2014. View Article : Google Scholar : PubMed/NCBI
22	Nakagawa K, Haga A, Kida S, Masutani Y, Yamashita H, Takahashi W, Sakumi A, Saotome N, Shiraki T, Ohtomo K, et al: 4D registration and 4D verification of lung tumor position for stereotactic volumetric modulated arc therapy using respiratory-correlated cone-beam CT. J Radiat Res. 54:152–156. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ and Senan S: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 70:685–692. 2008. View Article : Google Scholar : PubMed/NCBI
24	Thomas TO, Hasan S, Small W Jr, Herman JM, Lock M, Kim EY, Mayr NA, Teh BS and Lo SS: The tolerance of gastrointestinal organs to stereotactic body radiation therapy: What do we know so far? J Gastrointest Oncol. 5:236–246. 2014.PubMed/NCBI
25	Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V and Videtic GM: Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: Risk factors for late toxicity. Int J Radiat Oncol Biol Phys. 90:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
26	Pham AH, Yorke E, Rimner A and Wu AJ: Potential for interfraction motion to increase esophageal toxicity in lung SBRT. Technol Cancer Res Treat: 1533034617711353. 2017. View Article : Google Scholar
27	Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA and Swisher SG: Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 7:1522012. View Article : Google Scholar : PubMed/NCBI
28	Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP and Bezjak A: Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys. 82:967–973. 2012. View Article : Google Scholar : PubMed/NCBI
29	Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y and Itami J: Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 186:274–279. 2010. View Article : Google Scholar : PubMed/NCBI
30	Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De Ridder M and Storme G: Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Results of a Phase II trial. Int J Radiat Oncol Biol Phys. 80:1343–1349. 2011. View Article : Google Scholar : PubMed/NCBI
31	Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, et al: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 101:1623–1631. 2004. View Article : Google Scholar : PubMed/NCBI
32	Andratschke N, Zimmermann F, Boehm E, Schill S, Schoenknecht C, Thamm R, Molls M, Nieder C and Geinitz H: Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure. Radiother Oncol. 101:245–249. 2011. View Article : Google Scholar : PubMed/NCBI
33	Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G and Denning MD: Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: The pattern of failure is distant. Int J Radiat Oncol Biol Phys. 77:1146–1150. 2010. View Article : Google Scholar : PubMed/NCBI
34	Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC and Decker RH: Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 7:1394–1399. 2012. View Article : Google Scholar : PubMed/NCBI
35	Milano MT, Chen Y, Katz AW, Philip A, Schell MC and Okunieff P: Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol. 91:301–306. 2009. View Article : Google Scholar : PubMed/NCBI
36	Oskan F: The quality of toxicity reporting and the story of the lung SBRT ‘NO-FLY ZONe’. Int J Radiat Oncol Biol Phys. 92:514–515. 2015. View Article : Google Scholar : PubMed/NCBI
37	Timmerman RD: The quality of toxicity reporting and the story of the lung SBRT ‘No-Fly Zone’. In Regard to Oskan. Int J Radiat Oncol Biol Phys. 93:726–727. 2015. View Article : Google Scholar : PubMed/NCBI
38	Haasbeek CJ, Lagerwaard FJ, Slotman BJ and Senan S: Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 6:2036–2043. 2011. View Article : Google Scholar : PubMed/NCBI
39	Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG and Roth JA: Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: How to fly in a ‘no fly zone’. Int J Radiat Oncol Biol Phys. 88:1120–1128. 2014. View Article : Google Scholar : PubMed/NCBI
40	Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA and Chang JY: Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol. 112:256–261. 2014. View Article : Google Scholar : PubMed/NCBI
41	Senthi S, Haasbeek CJ, Lagerwaard FJ, Verbakel WF, de Haan PF, Slotman BJ and Senan S: Radiotherapy for a second primary lung cancer arising post-pneumonectomy: Planning considerations and clinical outcomes. J Thorac Dis. 5:116–122. 2013.PubMed/NCBI
42	Donington JS, Miller DL, Rowland CC, Deschamps C, Allen MS, Trastek VF and Pairolero PC: Subsequent pulmonary resection for bronchogenic carcinoma after pneumonectomy. Ann Thorac Surg. 74:154–159. 2002. View Article : Google Scholar : PubMed/NCBI
43	Rowell NP and Williams CJ: Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): A systematic review. Thorax. 56:628–638. 2001. View Article : Google Scholar : PubMed/NCBI
44	Lagerwaard FJ, Voet PW, van Meerbeeck JP, Burgers SA and Senan S: Rotterdam oncological thoracic study group: Curative radiotherapy for a second primary lung cancer arising after pneumonectomy-techniques and results. Radiother Oncol. 62:21–25. 2002. View Article : Google Scholar : PubMed/NCBI
45	Zhou J, Amrane S, Korkut DN, Bourdoncle A, He HZ, Ma DL and Mergny JL: Combination of i-motif and G-quadruplex structures within the same strand: Formation and application. Angew Chem Int Ed Engl. 52:7742–7746. 2013. View Article : Google Scholar : PubMed/NCBI
46	Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F and Donnadieu E: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 122:899–910. 2012. View Article : Google Scholar : PubMed/NCBI
47	He HZ, Chan DS, Leung CH and Ma DL: G-quadruplexes for luminescent sensing and logic gates. Nucleic Acids Res. 41:4345–4359. 2013. View Article : Google Scholar : PubMed/NCBI
48	Ma DL, He HZ, Leung KH, Chan DS and Leung CH: Bioactive luminescent transition-metal complexes for biomedical applications. Angew Chem Int Ed Engl. 52:7666–7682. 2013. View Article : Google Scholar : PubMed/NCBI
49	Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, et al: Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 17:547–559. 2010. View Article : Google Scholar : PubMed/NCBI
50	Leung CH, Zhong HJ, Yang H, Cheng Z, Chan DS, Ma VP, Abagyan R, Wong CY and Ma DL: A metal-based inhibitor of tumor necrosis factor-α. Angew Chem Int Ed Engl. 51:9010–9015. 2012. View Article : Google Scholar : PubMed/NCBI